Special Issue

Small-Molecule Inhibitors for Novel Therapeutics

Message from the Guest Editors

Small-molecule inhibitors represent a promising frontier in the development of novel therapeutics. These compounds are designed to specifically interact with and inhibit the function of target proteins that play critical roles in disease processes. By binding to these proteins, small-molecule inhibitors can disrupt pathological signaling pathways, offering a strategic approach to treating conditions such as cancer, autoimmune disorders, and infectious diseases. Recent advances in molecular biology and high-throughput screening have enabled the identification of previously undruggable targets, expanding the potential applications of these inhibitors. This Special Issue aims to describe recent developments in the research on small molecules, with a focus on enhancing their specificity, potency, and safety profiles toward novel therapeutic targets; small molecules drug delivery. Original research articles and reviews are welcome. You may choose our Joint Special Issue in Pharmaceuticals.

Guest Editors

Dr. Gustavo Provensi

Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA)—Pharmacology and Toxicology Session, University of Florence (UNIFI), 50139 Florence, Italy

Dr. Simone Giovannuzzi

NEUROFARBA Department, Pharmaceutical and Nutraceutical Section, University of Florence, Via U. Schiff 6, Sesto Fiorentino, 50019 Florence, Italy

Deadline for manuscript submissions

20 August 2025



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/207647

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

